Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OTLC | 8-K | neutral | 5/10 | Oncotelic Therapeutics completed a multi-step transaction (May 1, 2026) contributing its patent portfolio to Lunai Biowo | May 5, 2026 |
| CYTK | CLUSTER | mixed | 4/10 | Multiple CYTK insiders, including CFO and CCO, sold shares totaling $4.53M on the same day as Q1 2026 earnings release s | May 5, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics sold a combined $2.39M in open-market stock on May 5, 2026, the same day the company report | May 5, 2026 |
| ADPT | 8-K | bullish | 8/10 | Adaptive Biotechnologies reported Q1 2026 revenue of $70.9M (up 35% YoY), beating consensus estimates on EPS ($-0.13 vs | May 5, 2026 |
| CYTK | 8-K | neutral | 3/10 | Cytokinetics released a corporate presentation updating on commercial launch progress of MYQORZO (aficamten) for oHCM, p | May 5, 2026 |
| PTGX | 8-K | bullish | 7/10 | Protagonist Therapeutics reported Q1 2026 revenue of $56.4M and GAAP EPS of $0.05, significantly exceeding consensus est | May 5, 2026 |
| RIGL | 8-K | bearish | 7/10 | Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY r | May 5, 2026 |
| SDGR | 8-K | mixed | 5/10 | Schrödinger reported Q1 2026 total revenue of $58.6M (down 2% YoY but 23% above consensus), GAAP EPS of -$0.81 (vs conse | May 5, 2026 |
| DNTH | 8-K | bullish | 7/10 | Dianthus Therapeutics reported Q1 2026 net loss of $40.8M ($0.85/share) and highlighted major pipeline progress: early G | May 5, 2026 |
| RARE | PRESS-RELEASE | bearish | 6/10 | Ultragenyx reported Q1 2026 revenue of $136M (consensus $158.4M) and EPS of -$1.84 (consensus -$1.46), both missing expe | May 5, 2026 |
| AVTX | PRESS-RELEASE | bullish | 8/10 | Avalo Therapeutics announced positive Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa, meeting th | May 5, 2026 |
| PHVS | CLUSTER | neutral | 4/10 | Three Pharvaris insiders (CMO, Chief Early Development, Director) sold a combined ~$2.19M in open-market transactions ov | May 5, 2026 |
| FTLF | PRESS-RELEASE | neutral | 2/10 | FitLife Brands announced it will report Q1 2026 financial results on May 14, 2026. No preliminary financial data or guid | May 5, 2026 |
| LEEEF | 8-K | neutral | 5/10 | Leef Brands completed its merger with Standard Holdings, Inc. (SHI) on March 27, 2026, issuing approximately 13.7 millio | May 5, 2026 |
| SCLXW | 8-K | bullish | 8/10 | Scilex's indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in exchange f | May 5, 2026 |
| SCLX | PRESS-RELEASE | bullish | 8/10 | Scilex's indirect subsidiary, ACEA Therapeutics, has agreed to sell ACEA Pharma to Phoenix Asia Holdings in exchange for | May 5, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK granted a deferred investment award of notional ordinary shares to new Chief People Officer Roanne Parry under its l | May 5, 2026 |
| APUS | 8-K | neutral | 2/10 | Apimeds Pharmaceuticals US appointed Sungjoon Chae as Co-CEO effective May 4, 2026, following a stockholder nomination. | May 5, 2026 |
| VALN | 6-K | neutral | 2/10 | Valneva announced it will report Q1 2026 financial results on May 13, 2026. The press release contains no financial data | May 5, 2026 |
| OCGN | 8-K | mixed | 6/10 | Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5 | May 5, 2026 |
| JNJ | COURT-RULING | neutral | 3/10 | Janssen (JNJ) and Tolmar jointly moved to remand patent infringement appeals after reaching a settlement. The Federal Ci | May 5, 2026 |
| QNRX | ANALYST-UPGRADE | bullish | 2/10 | Lucid Capital Markets initiated coverage on Quanterix (QNRX) with a Buy rating and a $30 price target, representing a 37 | May 5, 2026 |
| TERN | 8-K | neutral | 8/10 | Terns Pharmaceuticals has been acquired by Merck Sharp & Dohme in a completed all-cash merger. The tender offer expired | May 5, 2026 |
| ASRT | 8-K | neutral | 3/10 | Assertio Holdings and Garda Therapeutics mutually agreed to postpone the commencement of the tender offer for all outsta | May 5, 2026 |
| TERN | 25-NSE | bearish | 9/10 | Nasdaq filed a Form 25-NSE to delist Terns Pharmaceuticals (TERN) common stock, effective immediately on May 5, 2026, un | May 5, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced the filing of a European patent application for novel psychedelic compounds targeting PTSD, | May 5, 2026 |
| XNCR | 8-K | bullish | 7/10 | Xencor reported final Phase 1 data for XmAb942, an anti-TL1A antibody for IBD, showing a terminal half-life of 74.1 days | May 5, 2026 |
| OCGN | PRESS-RELEASE | mixed | 6/10 | Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss w | May 5, 2026 |
| IRON | PRESS-RELEASE | neutral | 5/10 | Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63 | May 5, 2026 |
| IRON | 8-K | neutral | 4/10 | Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, d | May 5, 2026 |